US2012029207A1PendingUtilityA1
Novel Crystalline Form of Atorvastatin Hemi-calcium Salt, Hydrate Thereof, And Method of Producing The Same
Est. expiryJul 28, 2030(~4 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 9/10A61P 3/06A61P 25/28A61P 13/08C07D 207/34C07D 207/42C07D 207/36A61K 31/409A61P 19/10
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a novel crystalline form of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1, which is known to be useful as a drug, a hydrate thereof and a preparation method thereof:
Claims
exact text as granted — not AI-modified1 . A crystalline Form α atorvastatin hemi-calcium salt or a hydrate thereof, characterized by having peaks at 2θ values of 8.8, 9.6, 11.9, 16.9, 19.6, 21.7, 23.5, 26.9 and 29.7±0.5° in an X-ray powder diffraction.
2 . The crystalline Form α atorvastatin hemi-calcium salt or hydrate thereof of claim 1 , characterized by having peaks having a relative intensity greater than 10% at 2θ values of 8.8, 9.6, 11.9, 16.9, 19.6, 21.7, 23.5 and 29.7±0.5° in the X-ray powder diffraction.
3 . The crystalline Form α atorvastatin hemi-calcium salt or hydrate thereof of claim 1 , characterized by having broad peaks at 2θ values of 8.8, 9.6, 16.9, 21.7 and 23.5±0.5° in the X-ray powder diffraction.
4 . The crystalline Form α atorvastatin hemi-calcium salt or hydrate thereof of claim 1 , characterized by showing the X-ray powder diffraction spectrum as shown in FIG. 2 .
5 . The crystalline Form α atorvastatin hemi-calcium salt or hydrate thereof of claim 1 , characterized by showing the solid-state 13 C NMR spectrum as shown in FIG. 3 .
6 . A method for preparing a crystalline Form α atorvastatin hemi-calcium salt or a hydrate thereof, comprising the steps of: suspending a crude atorvastatin hemi-calcium salt in a mixed solvent of methanol and water; and stirring the suspension at a reaction temperature of 5˜25° C. for 1-10 hours.
7 . The method of claim 6 , wherein the volume ratio of methanol:water in the mixed solvent is 1:10(v/v)˜1:15(v/v), and the ratio of volume of the mixed solvent:weight of the crude atorvastatin hemi-calcium salt is 1:60˜65(v/wt).
8 . The method of claim 6 , wherein the reaction temperature is 10˜20° C.
9 . The method of claim 6 , wherein the stirring is carried out for 1-5 hours.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.